Compare
Abbott Laboratories vs Globus Medical (ABT vs GMED)
The two stocks side by side, as of the latest close. Performance is rebased to 100 at the start of the window.
Over the past year Abbott Laboratories (ABT) returned -11.7% and Globus Medical (GMED) +15.5%; so far this year the figures are -12.3% and -18.6%.
Abbott Laboratories is the larger company by market value, about 20.0 times the size of Globus Medical.
On trailing earnings, ABT trades at 40.9 times and GMED at 17.5 times.
Revenue grew +10.0% at ABT and +13.4% at GMED over the last year.
ABT yields 2.29%. GMED pays no dividend.
Data as of the latest close. Not investment advice.
Relative performance
| ABT | GMED | |
|---|---|---|
| Price | $109.93 | $71.05 |
| 1-day | -3.23% | -12.76% |
| YTD | -12.26% | -18.62% |
| 1 year | -11.73% | +15.51% |
| 3 years | +15.70% | +54.49% |
| Market cap | $190.4B | $9.5B |
| P/E | 40.9 | 17.5 |
| P/S | 3.95 | 3.04 |
| P/B | 3.73 | 1.99 |
| Revenue growth | +10.00% | +13.40% |
| EPS growth | -66.20% | +31.00% |
| Gross margin % | 56.9 | 69.1 |
| Net margin % | 9.7 | 17.8 |
| ROE % | 9.2 | 11.6 |
| Debt / equity | 0.61 | 0.00 |
| FCF yield % | 3.5 | 8.0 |
| Dividend yield % | 2.29 | — |
| Beta | 0.06 | 0.83 |
| RSI (14) | 58.5 | 38.7 |
| Technical rating |